1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | HT55 |
| Species | Human |
| Cat.No | ABC-TC0431 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Rectum |
| Disease | Rectal Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Colon Cancer Cell Lines |
HT-55 is a highly differentiated cancer cell line derived from adenocarcinoma of the rectum. In vitro, the adherent clumps of HT-55 exhibit a well-defined border consisting of a single cell layer, and these clumps of cells tend to resemble columnar epithelium. The growth pattern within these clumps involves the formation of multiple layers at the center, indicating that the cells grow in islands rather than a monolayer.
HT-55 presents desmosomes, which can be characteristic of endothelial cells. HT-55 can be cultured in EMEM (EBSS) with 2mM glutamine, 1% non-essential amino acids (NEAA), and 20% fetal bovine serum (FBS) at 5% CO2, 37°C; and also in DMEM with 10% FBS at 5% CO2, 32°C.
Why choose HT-55 from AcceGen?
HT-55 from AcceGen has a range of advantages. It exhibits exceptional sterility, as it has been extensively tested and confirmed to be free from bacterial, fungal, and mycoplasma contamination through PCR analysis. Our HT-55 displays remarkable cell viability after thawing. The identity of HT-55 is rigorously validated using Short Tandem Repeat (STR) analysis.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
HT-55 is a useful tool to elucidate the potential therapy of human rectal canceer. In studies involving HT-55, cell proliferation and death might be affected by anti-caner drugs via the signaling pathways of ERK 1/2, p38-MARK, and PI3K/AKT. Further investigation can explore the utilization of existing anti-cancer therapy targeting these pathways in HT-55. Moreover, a BRAF mutation (N581Y) has been detected in HT-55, suggesting HT-55 could be used to improve the strategy of combining anti-EGFR monoclonal antibodies with BRAF inhibitors for BRAF mutant cancers to elucidate the molecular pathogenesis of colorectal cancer.
